Autolus Therapeutics Reports First Quarter 2022 Financial Results and Operational Progress
May 05, 2022 07:00 ET
|
Autolus Therapeutics plc
LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Participate in Conferences During April 2022
March 29, 2022 07:00 ET
|
Autolus Therapeutics plc
- Wells Fargo Annual Biotech Forum on April 12 and 13 - - 21st Annual Needham Virtual Healthcare Conference on April 14 at 8:45am ET - - 14th Kempen Life Sciences Conference on April 21 -...
Autolus Therapeutics to Present at Conferences During January 2022
January 05, 2022 07:00 ET
|
Autolus Therapeutics plc
LONDON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to host Investor Conference Calls through June
May 26, 2020 07:00 ET
|
Autolus Therapeutics plc
LONDON, May 26, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Announces Conference Call to Review Clinical Data for Programmed T Cell Therapy Pipeline Presented at the 2019 ASH Annual Meeting
December 05, 2019 16:30 ET
|
Autolus Therapeutics plc
LONDON, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL) announced today that management will host a conference call and webcast on Monday, December 9, 2019 at 8:30 am ET /...
Autolus Therapeutics to Present at the Jefferies 2019 London Healthcare Conference
November 13, 2019 16:02 ET
|
Autolus Therapeutics plc
LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment...
Autolus Therapeutics and Noile-Immune Announce Licensing Agreement
November 13, 2019 06:30 ET
|
Autolus Therapeutics plc
LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, and Noile-Immune...
Autolus Therapeutics Presents Preclinical Data on AUT06NG at the SITC Annual Meeting
November 09, 2019 07:00 ET
|
Autolus Therapeutics plc
LONDON, Nov. 09, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment...
Autolus Therapeutics to Present Preclinical Data on AUT06NG at the SITC Annual Meeting
November 05, 2019 09:35 ET
|
Autolus Therapeutics plc
LONDON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment...
Autolus Announces Changes to Executive Leadership Team
October 08, 2019 08:00 ET
|
Autolus Therapeutics plc
LONDON, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...